Introduction {#s1}
============

Osteochondrosis (OC) is a developmental disease of growing horses. It is defined as a disturbance in the process of endochondral ossification ([@R17]). The disturbance can lead to the formation of detached fragments (osteochondrosis dissecans (OCD)), fissures, or subchondral bone cysts at the epiphyseal growth cartilage ([@R17], [@R27]). OCD is a frequent cause of pain, lameness and reduced performance in young athletic horses ([@R14], [@R26]).

The disease appears to be multifactorial in origin, including skeletal growth rates, nutrition, endocrinological factors, exercise, biomechanics and genetic effects ([@R7]). Several studies have demonstrated differentially expressed genes like, for example, Indian hedgehog (Ihh), transforming growth factor β 1 (TGF-β 1), Gli1 and insulin-like growth factor I (IGF-I) parathyroid hormone-related peptide (PTH-rP) in the cartilage of OC-affected horses ([@R21], [@R20], 2005, [@R30]).

In a previous study, we analysed the transcript profile of leukocytes from horses affected with OC using a high throughput sequencing method ([@R23]). Metabolic pathway analysis showed an obvious dysregulation of several signalling pathways related to cartilage formation and cartilage repair, such as Wnt, Indian hedgehog and TGF-β signalling pathways. Other genes that were differentially regulated may play a role in high-carbohydrate diet, abnormal insulin metabolism or inflammation ([@R23]). Horses of this study had a mean age of 2.5 years and were relatively old regarding the origin of the disease. OC occurs early in the age of the horse ([@R11]). The lesions undergo a variety of processes until they become visible as radiographic finding. Thereafter they may become modified by regenerative or degenerative processes ([@R6]). The global aim of our research is to find biomarkers of samples which can be easily obtained. The suitability of leukocytes for gene profiling is related to their active metabolism and accessibility by simple venipuncture ([@R12]). The aim of the present study is to investigate the leukocyte gene expression of horses of different age groups with OC lesions.

Materials and methods {#s2}
=====================

One hundred and thirty-five Belgian Warmblood horses were selected for this study, which followed a 'case control study' model. Selection was made on the base of the undoubtable results of the radiographies among the horses presented at the European Centre of the horse (Vielsalm, Belgium) by the breeders in the context of an orthopaedic diseases screening programme. OC-affected horses were classified into three different age groups: \<12 months (AGE 1, n=35), 18--24 months (AGE 2, n=38), \>30 months (AGE 3, n=26). Furthermore, 36 horses (AGE 1: n=12, AGE 2: n=12, AGE 3: n=12) without any evidence of OC lesions were selected and analysed as control groups.

All horses were sedated for the radiographic examination using detomidine (0.01 mg/kg intravenously) alone or combined with butorphanol (0.02 mg/kg intravenously). The following views were taken: lateromedial views of the four fetlocks, lateromedial and plantarolateral-dorsomedial oblique views of the hocks and a lateromedial view of the stifles. Horses were diagnosed on the basis of characteristic lesions of abnormal endochondral ossification located in the metacarpo and metarso phalangeal tibiotarsal, and femoro-patellar joints ([@R3]). Concerning the fetlock joint, fragmentation and irregularity observed on the dorsal aspect of the sagittal ridge and the condyles of the metacarpus or metatarsus were considered as OC lesions. Horses with dorsal, palmar or plantar fragmentations at the margin of the proximal phalanx were not included in this study. Concerning the hock, OC lesions were identified as fragments still in place (intermediate ridge) or surface irregularities of the trochlear ridge(s) or malleolus. Concerning the stifle joint, variably sized irregularity or flattening of the lateral trochlear ridge of the femur with sometimes partial calcification of the tissue within the defect were considered as OC lesions.

Horses with osteoarthritis and other radiological abnormalities, which were not clearly OC lesions, were excluded from this study. Blood was collected from each horse with PAXgene blood RNA tubes (BD Diagnostics, Le Pont de Claix, France) and frozen at −80°C for later analysis.

Total RNA was extracted from whole blood (2.5 ml) using the PAXgene blood RNA kit (Qiagen, Courtaboeuf, France). The integrity of total RNA extracted using the PAXgene method was checked by capillary electrophoresis analysis on Agilent BioAnalyser 2100 (Agilent, Palo Alto, California, USA). RNA quantity was measured using a spectrophotometer NanoDrop ND-1000 (Thermo Scientific, Les Ulis, France).

cDNA was synthesised using ∼300 ng of total RNA and performed, using the VILO reverse transcription Kit, according to the manufacturer\'s protocol (Invitrogen, Cergy Pontoise, France).

Pre-amplification was performed with a 22 pooled (final 0.2× of each) SYBR Green assay. After pre-amplification PCR, the product was treated with 4 U of Exonuclease I (NEB) then diluted 1:5 with 1× TE Buffer and stored in −80°C until needed. Quantitative PCR was carried out using the 96.96 dynamic array (Fluidigm Corporation, California, USA) following the manufacturer\'s protocol. Specifically, a 5 μl sample mixture was prepared for each sample containing 1× TaqMan Gene Expression Master Mix, 1× GE Sample Loading Reagent (Fluidigm PN 85000746), 1× EvaGreen (Interchim) and each of diluted pre-amplified cDNA. 5 μl of Assay mix was prepared with 1× each of SYBR Green assay and 1× Assay Loading Reagent (Fluidigm PN 85000736). An IFC controller was used to prime the fluidics array (chip) with control line fluid and then with samples and assay mixes in the appropriate inlets. After loading, the chip was placed in the BioMark Instrument for a first step of thermal mixing at 50°C for two minutes, 70°C for 30 minutes and 25°C for 10 minutes, then UNG & HotStart step at 50°C for two minutes followed by 95°C for two minutes. PCR was performed by 35 cycles at 95°C for 15 seconds and 60°C for one minute. Finally, melting curve was performed by increasing temperature from 60 to 95°C. The data were analysed with Real-Time PCR Analysis Software in the BIOMARK instrument (Fluidigm Corporation, California, USA).

RNA level quantification was assessed by calculating 2^−ΔΔCT^ ([@R19]).

In the previous study, we identified 2553 genes significantly upregulated or downregulated between the OC group and the control group ([@R23]). For this study, we have chosen 34 genes following different criteria: a low P value (inferior to 0.1 per cent), fold induction superior to 5, quality of annotation (existence of a lot of predicted mRNA in the horse genome), and a mix of upregulated and downregulated genes membership of a known signalling pathway ([Table 1](#VETRECO2014000058TB1){ref-type="table"}). Four control genes: WARS (tryptophanyl-tRNA synthetase), RIGE (retinoic acid induced gene E protein), B2M (β-2 microglobulin) and TUBB2C (tubulin, β 2C), referred to as housekeeping genes, were used to normalise mRNA levels between different samples. These four control genes were defined in a previous transcriptomic study ([@R23]).

###### 

List of the 33 genes selected on several criteria from [@R23]): a low P value (inferior to 0.1 per cent), fold induction superior to 5, quality of annotation, a mix of upregulated and downregulated genes membership of a known signalling pathway

  Gene symbol   Name                                                                             Transcript ID (Ensembl or Genbank)
  ------------- -------------------------------------------------------------------------------- ------------------------------------
  ADAMTLS4      ADAMTS-like protein 4 precursor                                                  ENSECAT00000020422
  ApoB          Apolipoprotein B                                                                 ENST00000233242
  ApoB3G        similar to ApoB mRNA editing enzyme catalytic polypeptide-like 3G                XM_001916520
  B4GALT6       β-1,4-galactosyltransferase 6                                                    ENSECAT00000018745
  BMP5          Bone morphogenetic protein 5                                                     ENSECAG00000007138
  CLK1          Dual specificity protein kinase                                                  ENSECAT00000016444
  CRKL          Crk-like protein                                                                 ENSECAT00000018670
  CSNK1E        Casein kinase I isoform epsilon                                                  ENSECAT00000023450
  CtBP1         C-terminal-binding protein 1                                                     ENSECAT00000016987
  CUL5          Cullin-5 (vasopressin-activated calcium-mobilising receptor)                     ENSECAT00000026414
  DVL1          Segment polarity protein dishevelled homologue DVL-1                             ENST00000378891
  DVL3          Segment polarity protein dishevelled homologue DVL-3                             ENSECAT00000009739
  FOXL1         Forkhead box L1                                                                  ENST00000320241
  FOXO1         Forkhead box O1                                                                  ENST00000379561
  FZD1          Frizzled family receptor 1                                                       ENSECAG00000001326
  GRB2          Growth factor receptor-bound protein 2                                           ENSECAG00000006524
  GSK3B         Glycogen synthase kinase 3 β                                                     ENSECAT00000026913
  Hp            Haptoglobin                                                                      XM_001497810
  IFIH1         Interferon induced with helicase C domain                                        ENST00000263642
  IKBKB         Inhibitor of nuclear factor κ-B kinase subunit β                                 ENSECAT00000005219
  ISG15         Interferon-induced protein precursor                                             ENSECAT00000001183
  MGAT4A        Mannosyl glycoproteinacetylglucosaminyltransferase                               ENSECAG00000015468
  MHCI          MHC class I heavy chain                                                          ENSECAT00000021999
  MHCIIa        Similar to MHC class II antigen DQ α chain                                       ENSECAT00000022398
  MMP1          Interstitial collagenase precursor (Matrix metalloproteinase-1)                  ENSECAT00000025715
  OAS3          2′-5′-oligoadenylate synthetase 3                                                ENST00000549918
  PPP1CB        Protein phosphatase 1, catalytic subunit, β isoform                              ENSECAG00000009359
  PPR2A         Protein phosphatase 2, regulatory subunit A, α isoform                           ENSECAT00000019754
  PRKCG         Protein kinase C, γ                                                              ENSECAT00000020980
  PYGL          Phosphorylase, glycogen, liver                                                   ENSECAT00000013037
  RUSC2         Iporin (interacting protein of Rab1) (RUN and SH3 domain-containing protein 2)   ENSECAT00000026463
  SECTM1        Secreted and transmembrane protein 1 precursor                                   ENSECAT00000006039
  SMAD5         SMAD family member 5                                                             ENSECAG00000000815
  TBC1D9        TBC1 domain family member 9B                                                     ENSECAT00000018936
  WASH1         WAS protein family homologue 1                                                   XM_001493185.2

Statistical analysis was performed according to [@R29] using the data of control groups as references values (ΔΔCT) respectively for each AGE. Then, the significance analysis of microarrays (SAM) method was used to compare the levels of gene expression as a marker of OC, taking into account the age effect between control samples and study samples. We used the corrected P value based on the false discovery rate (FDR) method ([@R24]). The results are expressed for each gene as a ratio between the expression levels in the OC-affected group versus the healthy horses. Our statistical criterion for the SAM analysis was the following: only the genes with a level of expression strictly below 0.7 or superior to 1.5 and satisfying at least a FDR strictly lower than 5 per cent were considered as possible biomarkers.

Results {#s3}
=======

The results of the SAM analysis were reported in [Table 2](#VETRECO2014000058TB2){ref-type="table"} for each age group. We found several biomarkers satisfying our biomarker selection criterion.

###### 

SAM-plot results with the overexpressed an underexpressed genes

                \<12 months   18--24 months   \>30 months                     
  ------------- ------------- --------------- ------------- ----- ----------- -------
  **MGAT4A**    **1.808**     0.0             **1.508**     0.0   **1.76**    3.2
  **PRKCG**     **1.83**      0.0                                             
  **MHCI**      **1.592**     0.0                                             
  **ApoB**      **2.965**     0.0                                             
  **ApoB3G**    **4.768**     0.0                                             
  **B4GALT6**   **2.185**     0.0                                             
  *OAS3*        *0.428*       *0.0*                               *0.648*     *0.0*
  **TBC1D9**                                  **1.89**      0.0               
  **IFIH1**                                   **2.35**      0.0               
  **MHCIIa**                                  **1.532**     0.0   **1.607**   3.2
  **MMP1**                                    **3.225**     0.0   **3.863**   3.2
  **HP**                                                          **3.072**   3.2
  **SECTM1**                                                      **3.301**   0.0
  **PYGL**                                                        **1.729**   3.2
  **CUL5**                                                        **1.812**   3.2
  **GSK3B**                                                       **1.519**   3.2
  *WASH1*                                                         *0.573*     *0.0*

The Ratio (\<0.7 and \>1.5) and the FDR (\<5 per cent) are reported with the overexpressed (bold) and underexpressed (italic) genes. The FDR is a corrected p value ([@R24])

SAM, significance analysis of microarrays

Relative expression of genes of horses less than 12 months of age showed significant induction of the genes MGAT4A (mannosyl-glycol-protein acetylglucosaminyltransferase), PRKCG (protein kinase C, gamma), MHCI (MHC class I, α chain), ApoB (apolipoprotein B), ApoB3G (similar to apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G), B4GALT6 (β-1,4-galactosyltransferase 6), the three latter genes were above the golden threshold of two-fold change. Further, there was a significantly lower expression of the gene OAS3 (2′5′-oligoadenylate synthetase 3) with a two-fold change.

Horses of 18--24 months of age, showed a significantly higher expression of the genes TBC1D9 (TBC1 domain family, member 9 (with GRAM domain)), MGAT4A, IFIH1 (interferon-induced helicase C domain-containing protein 1), MHCIIa (similar to MHC class I, α chain) and MMP1 (interstitial collagenase precursor), withIFIH1 and MMP1 above the two-fold change for upregulated genes.

Horses of more than 30 months of age showed a significantly higher expression of the genes MGAT4A, HP (haptoglobin), SECTM1 (secreted and transmembrane protein 1 precursor (protein K12)), MHCIIa, PYGL (phosphorylase, glycogen, liver), CUL5 (cullin-5, vasopressin-activated calcium mobilising receptor), GSK3B (glycogen synthase kinase 3 β) and MMP1. Again we found MMP1 above the golden two-fold change threshold. Two other genes are worth mentioning: SECTM1 and HP. For the downregulated genes a significant lower expression of OAS3 and WASH1 (WAS protein family homologue 1) were found by the SAM analysis.

Based on our very low FDR rates we computed [Fig 1](#VETRECO2014000058F1){ref-type="fig"} which combines in a Venn diagram the common markers between the groups. We found several common markers such as MGAT4A which is upregulated at all ages and could be seen as our 'supermarker', OAS3 as a common disease marker for groups of horses less than 12 months of age and horses of more than 30 months of age, and two common markers MHCIIa and MMP1 for horses of 18--24 months of age and horses of more than 30 months of age.

![Venn diagram showing the number of common markers between the three age groups](vetreco2014000058f01){#VETRECO2014000058F1}

Discussion {#s4}
==========

We previously demonstrated that leukocytes of affected horses showed differential expression of genes related to several metabolic pathways, for example, Wnt signalling, insulin signalling, TGF-β signalling and Ihh signalling ([@R23]). Mature leukocytes have been shown to express a variety of mRNAs and they are able to respond to external stimuli by rapid and complex changes in gene expression ([@R2]). Likewise, [@R12] considered peripheral blood leukocytes as a surrogate tissue to substitute for traditional tissue specimens that are not easily accessible. The suitability of leukocytes for gene profiling is related to their active metabolism and accessibility by simple venipuncture, which may allow a repeated time-series analysis of changes in gene expression in response to changing environmental or disease factors ([@R12]). In horses, [@R9] used a similar method to study the transcript profile of leukocytes from horses affected by osteoarthritis.

Histology studies ([@R10]) and cartilage-derived transcriptome studies have demonstrated timely changes in the initiation and the progression of the cartilage lesions. The initial step in the pathogenesis is one or several of the following events: formation of a fragile cartilage, failure of chondrocyte differentiation, subchondral bone necrosis, and failure of blood supply to the growth cartilage ([@R27], [@R16]). In the more chronic stages of the disease, secondary degenerative and regenerative processes overshadow the initial events ([@R1]). The timely fashion of the events is also reflected in the transcriptome changes of leukocytes of OC-affected horses compared with age-matched OC-free controls. However, the transcript level of the MGAT4A gene remains significantly higher in the OC-affected horses of all ages. This gene is implicated in the intracellular transport of glucose via the membrane localisation of GLUT2 ([@R8]). The MGAT4A transcript level is significantly higher in white blood cells of peripheral blood of human patients affected by type 2 diabetes (T2D) ([@R13]). They suggest that high levels of glucose and triglycerides could induce the high MGAT4A transcript levels, especially in subjects with a particular T2D genetic background. A similar explanation could be proposed for the OC-affected foals. In an animal model, transient hyperglycaemia causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. This mechanism implicates a mitochondrial pathway with a high superoxide anion production ([@R5]). Recently, abnormal mitochondria and endoplasmic reticulum were observed in the deep zone of OC cartilage ([@R4]). The mitochondrial dysfunction could be partially explained by the altered Wnt signalling pathway observed in the OC-affected horses because this pathway is known as a key regulator of mitochondrial function ([@R23], [@R28]).

Other genes identified as possible biomarkers in this study are related to the carbohydrate and lipid metabolism (APOB, TBC1D9, B4GALT6, PYGL, GSK3) or gene expression, cell growth, apoptosis and differentiation (APOB3G, PRKCG, CUL5, SECTM1, WASH1) or related to inflammatory and immune mechanisms (OAS3, MMP1, HP, IF1H1, MHCI, MHCIIa).

Their role in the pathogenesis of equine OC remains to be determined, but a high-energy diet is known to induce OC lesions in foals ([@R18], [@R15]). These observations were illustrated recently by [@R25]. It appears that mares fed with concentrates during gestation are more likely to produce foals that are subsequently affected by OC compared with other mares.

Even though the real-time PCR analysis of the 135 horses is conclusive, the potential markers should be subjected to individual analysis in order to validate their clinical potential. Limitations of this study include the fact that neither the affected joint nor other lesions of endochondral ossification such as subchondral cysts have been considered.

Even if the causal relationship between the differentially expressed genes and the development and progression of the OC lesions needs to be determined, this study clearly demonstrates that OC-affected horses show particular changes in their leukocyte transcriptome and that these modifications change with age.
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